COOPER COS INC/THE
COONASDAQTrading Snapshot
- Day Range
- $58.85 β $60.29
- 52-Week Range
- $51.01 β $89.83
- Volume (shares)
- 260,169
- Avg Volume (shares)
- β
- Shares Outstanding
- 190.2M
- Next Earnings
- 2026-12-03
Fundamentals Snapshot
- Annual Revenue
- $4.09B
- Last Q Revenue
- $1.07B
- P/E Ratio
- 20.1
- P/S Ratio
- 2.7x
- EPS (TTM)
- $2.93
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β1.5%
COOPER COS INC/THE
COOAbout COOPER COS INC/THE
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.